Immucell ( (ICCC) ) has released its Q1 earnings. Here is a breakdown of the information Immucell presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ImmuCell Corporation is a company in the animal health sector that develops, manufactures, and markets products aimed at improving the health and productivity of dairy and beef cattle.
In its latest earnings report for the quarter ended March 31, 2025, ImmuCell announced a record-setting performance with product sales reaching approximately $8.1 million, marking an 11% increase compared to the same period in 2024. The company also reported a record net income of approximately $1.4 million, a significant improvement from a net loss in the previous year.
Key financial highlights include a 42% gross margin, up from 37% in the previous quarter, and an increase in cash and cash equivalents to $4.6 million. The company’s net working capital and stockholders’ equity also saw notable increases. ImmuCell is actively working to reduce its backlog of orders and improve its production efficiency.
Looking ahead, ImmuCell is focusing on the investigational use of its Re-Tain product to gather market feedback and is exploring strategic options for its technology. The management remains optimistic about continuing to enhance production output and gross margins while reducing product development expenses.